Free Trial
NASDAQ:FBRX

Forte Biosciences Q2 2025 Earnings Report

Forte Biosciences logo
$10.58 +0.88 (+9.07%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$10.38 -0.20 (-1.89%)
As of 08/6/2025 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$1.21
Beat/Miss
N/A
One Year Ago EPS
N/A

Forte Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Forte Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Forte Biosciences Earnings Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
Forte Biosciences Inc News (FBRX) - Investing.com
See More Forte Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email.

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

View Forte Biosciences Profile

More Earnings Resources from MarketBeat